miR-200b has been implicated in targeting PD-L1 and inhibiting IFN-γ-stimulated PD-L1 expression in gastric cancer, while miR-200c targets PD-L1 in HBV+ human liver cell lines and acute myeloid leukemia [87,88]. Here, IFNG is linked to acute myeloid leukemia.